Immutep (NASDAQ:IMMP) Upgraded by Wall Street Zen to "Hold" Rating

Immutep (NASDAQ:IMMP - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Thursday.

Immutep Stock Up 0.5%

NASDAQ IMMP traded up $0.01 during trading hours on Thursday, hitting $1.95. The company had a trading volume of 31,456 shares, compared to its average volume of 220,065. Immutep has a fifty-two week low of $1.32 and a fifty-two week high of $3.27. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01. The firm's 50 day moving average is $1.74 and its 200 day moving average is $1.89.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. ABC Arbitrage SA bought a new stake in shares of Immutep during the fourth quarter valued at approximately $152,000. XY Capital Ltd increased its stake in Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock valued at $357,000 after buying an additional 56,306 shares during the period. Two Sigma Securities LLC acquired a new stake in shares of Immutep in the 4th quarter worth approximately $74,000. OLD Mission Capital LLC acquired a new stake in Immutep in the fourth quarter worth approximately $36,000. Finally, Fortitude Advisory Group L.L.C. bought a new stake in shares of Immutep in the 4th quarter worth $28,000. 2.32% of the stock is currently owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.